BC Innovations | Dec 19, 2019
Distillery Therapeutics

CXCR2 inhibition could overcome androgen receptor antagonist resistance in prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Inhibiting CXCR2 could treat androgen receptor antagonist-resistant prostate cancer. Knockout of CXCR2, which is found on treatment-resistant, androgen receptor-negative neuroendocrine tumor cells in heterogeneous prostate cancers, restored sensitivity to...
BC Extra | Jul 31, 2019
Company News

July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

Biktarvy, Yescarta beat estimates  Gilead Sciences Inc. (NASDAQ:GILD) raised its 2019 sales guidance after reporting higher-than-expected 2Q19 earnings driven by sales of HIV drug Biktarvy bictegravir/emtricitabine/tenofovir alafenamide and CAR T therapy Yescarta axicabtagene ciloleucel. Biktarvy...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

Earnings on deck At least 27 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Fiscal 1Q Company Date Pre/post mkt 2Q19...
BC Extra | Jul 1, 2019
Company News

July 1 Company Quick Takes: Alnylam submits MAA for hepatic porphyria therapy; plus Sage, Amicus and PTC

Alnylam submits hepatic porphyria therapy MAA  Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) submitted an MAA to EMA for givosiran to treat acute hepatic porphyria. Last month, the biotech completed a rolling NDA for the subcutaneous RNAi therapeutic...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Innovations | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
BC Extra | May 17, 2019
Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

Takeda's Gattex gets pediatric approval  FDA approved Gattex teduglutide from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to include treatment of patients age one and older with short bowel syndrome who are dependent on parenteral support,...
BioCentury | Apr 26, 2019
Finance

Earnings on deck

Earnings on deck At least 17 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 2Q; (B) During trading hours in Europe; premarket on U.S. exchange Company Date Pre/post mkt 1Q19...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Innovations | Apr 2, 2019
Distillery Therapeutics

Conbriza bazedoxifene for MS and other demyelinating diseases

DISEASE CATEGORY: Autoimmune disease; neurology INDICATION: Multiple sclerosis (MS); neurology Cell culture and mouse studies suggest Conbriza bazedoxifene could help treat MS and other demyelinating diseases. In oligodendrocyte precursor cells (OPCs) derived from a human...
Items per page:
1 - 10 of 846
BC Innovations | Dec 19, 2019
Distillery Therapeutics

CXCR2 inhibition could overcome androgen receptor antagonist resistance in prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Inhibiting CXCR2 could treat androgen receptor antagonist-resistant prostate cancer. Knockout of CXCR2, which is found on treatment-resistant, androgen receptor-negative neuroendocrine tumor cells in heterogeneous prostate cancers, restored sensitivity to...
BC Extra | Jul 31, 2019
Company News

July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

Biktarvy, Yescarta beat estimates  Gilead Sciences Inc. (NASDAQ:GILD) raised its 2019 sales guidance after reporting higher-than-expected 2Q19 earnings driven by sales of HIV drug Biktarvy bictegravir/emtricitabine/tenofovir alafenamide and CAR T therapy Yescarta axicabtagene ciloleucel. Biktarvy...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

Earnings on deck At least 27 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Fiscal 1Q Company Date Pre/post mkt 2Q19...
BC Extra | Jul 1, 2019
Company News

July 1 Company Quick Takes: Alnylam submits MAA for hepatic porphyria therapy; plus Sage, Amicus and PTC

Alnylam submits hepatic porphyria therapy MAA  Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) submitted an MAA to EMA for givosiran to treat acute hepatic porphyria. Last month, the biotech completed a rolling NDA for the subcutaneous RNAi therapeutic...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Innovations | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
BC Extra | May 17, 2019
Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

Takeda's Gattex gets pediatric approval  FDA approved Gattex teduglutide from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to include treatment of patients age one and older with short bowel syndrome who are dependent on parenteral support,...
BioCentury | Apr 26, 2019
Finance

Earnings on deck

Earnings on deck At least 17 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 2Q; (B) During trading hours in Europe; premarket on U.S. exchange Company Date Pre/post mkt 1Q19...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Innovations | Apr 2, 2019
Distillery Therapeutics

Conbriza bazedoxifene for MS and other demyelinating diseases

DISEASE CATEGORY: Autoimmune disease; neurology INDICATION: Multiple sclerosis (MS); neurology Cell culture and mouse studies suggest Conbriza bazedoxifene could help treat MS and other demyelinating diseases. In oligodendrocyte precursor cells (OPCs) derived from a human...
Items per page:
1 - 10 of 846